|Articles|October 5, 2018

Front Range Biosciences Raises $10 Million for Cannabis Research

Front Range Biosciences (FRB), a leading agricultural biotech company specializing in tissue culture propagation of high value crops, announced in a press release on October 4, 2018 (1), that it has completed a $10 million Series A round of financing for cannabis research.

Front Range Biosciences (FRB), a leading agricultural biotech company specializing in tissue culture propagation of high value crops, announced in a press release on October 4, 2018 (1), that it has completed a $10 million Series A round of financing for cannabis research.

"This financing will help us accelerate our Clean Stock program in Colorado, California, and Canada, in addition to aggressively pursuing IP development and resourcing our varietal development program for hemp and cannabis," said Dr. Jonathan Vaught, CEO and co-founder of FRB, in the press release. "As cannabis and hemp legalization spreads throughout the United States and internationally, there is an increase in demand for clean, quality crops-this capital will also enable us to expand our capacity to meet a small portion of that demand. We appreciate the support from our early investors and are pleased to welcome new investors to the family as we execute on our mission to provide growers with a wide variety of disease-free and true-to-type plant stock."

According to the company’s website (2), the Clean Stock program provides cannabis, hemp, and coffee producers with pesticide-free, virus-free, true-to-type plants by using the best practices in agricultural technology. FRB's Clean Stock program reportedly leverages tissue culture, the sterile propagation of baby plants through duplication on a nutrient culture medium of known composition, to solve operational problems such as disease, inefficiency, inconsistency and scale.

Investors reportedly include Phyto Partners, WelCan Capital, Salveo Capital, Cornerstone Opportunity Partners, Sand Hill Angels, Harvard Business School Alumni Angels of New York, New York Angels, Altitude Investment Management, and other new and returning investors. FRB has completed the largest fundraising by a U.S. cannabis biotech company to date.

References:

  1. https://www.prnewswire.com/news-releases/front-range-biosciences-raises-10-million-in-series-a-financing-300724344.html?utm_source=website&utm_medium=organic&utm_campaign=press_release
  2. http://www.frontrangebio.com/?utm_source=press_list&utm_medium=press_release

Related to this article

2025 Medical Cannabis Roundup
Let’s take a look at the 2025 cannabis coverage on medical cannabis research and medicine to catch up on industry trends and innovations.
Image | adobe.stock/Stock Rocket
Let’s take a look at the 2025 cannabis coverage on cannabis research to catch up on industry trends and innovations.
Image | adobe.stock/Maksim Kabakou
It’s that time of year again—the Cannabis Science and Technology (CST) top 10 articles from the previous year. CST published a wide variety of content throughout 2025. Here is just a small snippet of some of the top articles that our readers enjoyed. See if any of your favorites made the list!
Best of the Week: December 12 – December 18, 2025
Our top cannabis news topics this week: President Trump’s executive order on cannabis rescheduling, hemp regulation legislation, NY program using cannabis to reduce opioid use, cannabis genetics and cannabinoid profiles, and the latest cannabis research studies.